Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01840540 · ClinicalTrials.gov registry record · Phase 1
MSC for Occlusive Disease of the Kidney
A Phase 1 study of Renovascular Hypertension and Atherosclerotic Renal Artery Stenosis, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01840540 is a Phase 1 study of Renovascular Hypertension and Atherosclerotic Renal Artery Stenosis that has completed, run by Mayo Clinic. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01840540, a Phase 1 study of Renovascular Hypertension and Atherosclerotic Renal Artery Stenosis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety and toxicity of intra-arterial infused autologous adipose derived mesenchymal stromal (stem) cells in patients with vascular occlusive disease of the kidney.
Conditions Studied
Interventions
- DRUG Arterial infusion of autologous mesenchymal stem cells
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01840540
The ClinicalTrials.gov registry entry for NCT01840540 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Renovascular Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Arterial infusion of autologous mesenchymal stem cells is the first listed.
NCT01840540 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01840540 about?
NCT01840540 is a clinical study titled "MSC for Occlusive Disease of the Kidney". To determine the safety and toxicity of intra-arterial infused autologous adipose derived mesenchymal stromal (stem) cells in patients with vascular occlusive disease of the kidney.
What is the current status of trial NCT01840540?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-04. Estimated completion is 2017-04.
What conditions does trial NCT01840540 study?
This clinical trial studies the following conditions: Renovascular Hypertension, Atherosclerotic Renal Artery Stenosis, Ischemic Nephropathy.
What interventions are being tested in trial NCT01840540?
The interventions under investigation include: Arterial infusion of autologous mesenchymal stem cells (DRUG).
Who is sponsoring clinical trial NCT01840540?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01840540 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renovascular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Renovascular Hypertension
All registered trials for this condition
Atherosclerotic Renal Artery Stenosis
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.